Breaking the RAAS Cycle: ACE Inhibition in Heart and Kidney Disease

Asthma: Dreams of Anticholinergics

Asthma treatment wasn’t always built around inhalers. It once came from poisonous plants, smoke, and a mysterious dream. In this episode, we explore the strange history of anticholinergics, tracing the path from Jimsonweed and belladonna to atropine, acetylcholine, and Otto Loewi’s discovery of “Vagusstoff.” We follow how Loewi’s frog-heart experiment helped prove that nerves communicate through chemical messengers, and how Henry Dale’s work connected those discoveries to the vagus nerve and airway constriction. We examine why early plant-based asthma remedies could open the airways while also causing dangerous side effects, and how that understanding eventually led to modern anticholinergic therapy. This episode reveals how a dream, a frog heart, and a toxic smoke helped shape the pharmacology of asthma.

Asthma: From the Greeks to Albuterol How Science Unraveled the Airways

Asthma wasn’t always a diagnosis—it was once just a word for breathlessness. In this episode, we explore how asthma evolved from a nonspecific symptom into a defined disease of the small airways. From early descriptions in Greek medicine to the pathologic insights of Morgagni and the mechanistic thinking of Henry Hyde Salter, we follow the key discoveries that shaped our understanding of asthma. We examine how airway inflammation, bronchospasm, mucus plugging, and allergic responses were gradually identified as central features of the disease. This episode sets the stage for understanding the modern pathophysiology of asthma and the therapies that followed.

Breaking the RAAS Cycle: ACE Inhibition in Heart and Kidney Disease

From the discovery of a mysterious blood-pressure–lowering effect in the venom of a Brazilian pit viper to the development of the first ACE inhibitor, we trace how scientists transformed a deadly toxin into lifesaving medicine. We follow the work that identified bradykinin-potentiating peptides in snake venom and revealed that angiotensin-converting enzyme could be blocked—leading to the creation of captopril and later drugs such as enalapril and lisinopril. Along the way, landmark experiments and clinical trials showed that ACE inhibitors do far more than lower blood pressure, reshaping the treatment of heart failure and chronic kidney disease by targeting maladaptive activation of the renin–angiotensin–aldosterone system.

ACE Inhibitors, RAAS Physiology, and Snake Venom: Renin, Angiotensin, and Kidney Blood Pressure Control

From grinding up kidneys and injecting the extracts into animals to the famous Goldblatt clamp experiment, we trace decades of bold science that uncovered the body's most elaborate blood pressure system piece by piece. In part one of a two-part story, we follow the kidney's rise from simple filter to master regulator — through the discovery of renin, the bitter 17-year naming rivalry between Buenos Aires and Cleveland, and the identification of the enzyme that activates it all. Along the way, we encounter a Brazilian pit viper whose venom holds a molecular clue to one of modern medicine's greatest breakthroughs.

Mercury, the First Antibiotic, and the Birth of Thiazide Diuretics

From mercury injections in early syphilis and heart failure patients to the discovery of carbonic anhydrase and the rise of sulfa drugs, we follow how physicians first learned to manipulate fluid balance. We also explore the development of acetazolamide and the eventual breakthrough of thiazide diuretics—revealing how observation and experimentation reshaped the treatment of heart failure and high blood pressure.